Quick Answer
Citius Pharmaceuticals, Inc. reported Operating Income Loss of -$38.53 million for the year ending 2025.
- Citius Pharmaceuticals, Inc. showed an increase of +8.3% in Operating Income Loss from 2024 to 2025.
- This data is from Citius Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on December 23, 2025.
- XBRL data for this metric is available from 2010 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$49.8 thousand | Q2 2014: -$1.3 thousand | Q4 2014: -$878.9 thousand | Q1 2015: -$608.9 thousand | Q2 2015: -$773.7 thousand | Q4 2015: -$1.24 million | Q1 2016: -$671.6 thousand | Q2 2016: -$2.13 million | Q4 2016: -$2.78 million | Q1 2017: -$2.54 million | Q2 2017: -$2.26 million | Q4 2017: -$3.24 million | Q1 2018: -$4.87 million | Q2 2018: -$2.02 million | Q4 2018: -$3.87 million | Q1 2019: -$3.64 million | Q2 2019: -$4.43 million | Q4 2019: -$4.45 million | Q1 2020: -$4.43 million | Q2 2020: -$4.69 million | Q4 2020: -$8.16 million | Q1 2021: -$4.19 million | Q2 2021: -$5.98 million | Q4 2021: -$9.26 million | Q1 2022: -$7.59 million | Q2 2022: -$8.92 million | Q4 2022: -$7.25 million | Q1 2023: -$10.69 million | Q2 2023: -$8.67 million | Q4 2023: -$9.34 million | Q1 2024: -$10.97 million | Q2 2024: -$10.63 million | Q4 2024: -$10.04 million | Q1 2025: -$11.26 million | Q2 2025: -$8.79 million | Q4 2025: -$9.02 million.
- Over the full 17 years of available data (2010 to 2025), Citius Pharmaceuticals, Inc.'s Operating Income Loss has declined by 248,452.3%.
- Historical annual values: Fiscal year 2025: -$38.53 million | Fiscal year 2024: -$42.00 million | Fiscal year 2023: -$36.73 million | Fiscal year 2022: -$33.32 million | Fiscal year 2021: -$23.53 million | Fiscal year 2020: -$17.71 million | Fiscal year 2019: -$15.60 million | Fiscal year 2018: -$13.79 million | Fiscal year 2017: -$9.99 million | Fiscal year 2016: -$7.45 million | Fiscal year 2015: -$3.23 million | Fiscal year 2014: -$653.8 thousand | Fiscal year 2013: -$1.18 million | Fiscal year 2013: -$28.1 thousand | Fiscal year 2012: -$19.6 thousand | Fiscal year 2011: -$25.6 thousand | Fiscal year 2010: -$15.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: